LifeMine Therapeutics

Biotech discovering drugs from fungal-derived natural products, with lead candidate LIFE-001 for preventing organ transplant rejection.

View on the globe

$263MEquity raised in 2025–20262025 — · 2026 $263M · 2 equity rounds
$263MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from 6 Aug 2026 to 6 Aug 2026, $263M equity disclosed. Earlier rounds exist but are not sourced.6 Aug 2026: Series D, $75M; 6 Aug 2026: Series E, $188M$1M$3M$10M$30M$100M$300MEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 20172026Q2Q3Q42027Q2Equity round6 Aug 2026 · Series E · $188M · led by Milky Way Investments6 Aug 2026 · Series D · $75MSeries E · $188MSeries D · $75M
Funding history: 2 rounds from 6 Aug 2026 to 6 Aug 2026, $263M equity disclosed. Earlier rounds exist but are not sourced.6 Aug 2026: Series D, $75M; 6 Aug 2026: Series E, $188M$1M$3M$10M$30M$100M$300MEarlier rounds exist but are not sourced yetearlier rounds not sourced’17Q2Q3Q42027Q2Equity round6 Aug 2026 · Series E · $188M · led by Milky Way Investments6 Aug 2026 · Series D · $75M$188M$75M

Funding history 2 rounds · 3 sources · newest first

Earlier rounds not yet sourced. LifeMine Therapeutics was founded in 2017 and raised before 6 Aug 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series E
    Amount$188M
    Post-money—
    ✓ Confirmed
    Lead
    Milky Way Investments
    Also
    Bezos Expeditions, Gates Frontier, GV, RA Capital Management, ARCH Venture Partners
    Note
    The company's $263M headline combines the ~$75M Series D and this $188M Series E (per BioPharma Dive).
    Sources
  2. Series D
    Amount$75M
    Post-money—
    ◔ Reported
    Note
    Disclosed alongside the Series E on 2026-08-06; BioPharma Dive says the roughly $75M was raised in Q4 2025 (previously undisclosed), so the announcement date is used. Investors not named.
    Sources
  3. Earlier rounds not yet sourced

Investors 6

  • Milky Way Investments1
  • ARCH Venture Partners
  • Bezos Expeditions
  • Gates Frontier
  • GV
  • RA Capital Management

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. LifeMine Therapeutics and its logo are trademarks of their owners, used here for identification only.